Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 1;12:744578. doi: 10.3389/fphar.2021.744578

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Guo, Zhu, Ye, Wang, Yang, Huang, Shu, Zhang, Zhou and Li.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The anti-cancer effect of YRDC might affect the KRAS protein levels, but not mRNA levels. (A) The knockdown of YRDC attenuates cellular sensitivity to trametinib. After inhibiting the activity of the MAPK pathway, the expression of YRDC no longer affected the sensitivity of lenvatinib. (B) The mRNA expression levels of KRAS in overexpression, knockdown, and control in Huh7 cell. (C) The protein expression levels of YRDC and KRAS in overexpression, knockdown, and control in the Huh7 cells. (D) t⁶A levels in four kinds of Huh7 cells with different YRDC expression. (E) The fluorescent activity in addition of tRNAs from four kinds of Huh7 cells with different expressions in vitro reticulocytes translation system. (F) The KRAS level in addition of tRNAs from four kinds of Huh7 cells with different expressions in vitro reticulocytes translation system. Dots in the graphs mean biological repetitions, n = 3.